Illumina, Inc. (NASDAQ:ILMN) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on Illumina, with eight buy ratings, six holds, two sells and one strong-buy rating. The average 12-month price target is $188.40, below the reported share price of $193.13.
• Illumina exceeded quarterly expectations, reporting $1.31 in earnings per share versus a $1.23 estimate and $1.16 billion in revenue, up 9.4% year over year. The company projects fiscal-year 2026 EPS of $5.30–$5.40.
• Insiders sold 1.42 million shares worth approximately $256 million over the past three months, while institutional investors and hedge funds own 89.42% of the company.

Shares of Illumina, Inc. (NASDAQ:ILMN - Get Free Report) have earned an average rating of "Hold" from the seventeen analysts that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $188.40.

A number of research firms recently weighed in on ILMN. Guggenheim upped their price target on Illumina from $200.00 to $226.00 and gave the stock a "buy" rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft cut Illumina to a "hold" rating in a report on Wednesday, August 5th. Citigroup raised their price target on Illumina from $95.00 to $113.00 and gave the company a "sell" rating in a research report on Monday, August 3rd. Canaccord Genuity Group lifted their price target on Illumina from $190.00 to $205.00 and gave the stock a "hold" rating in a research note on Monday, August 3rd. Finally, Evercore reiterated an "outperform" rating on shares of Illumina in a research report on Monday, July 6th.

Illumina Stock Up 1.2%

Shares of NASDAQ ILMN opened at $193.13 on Tuesday. The stock has a market capitalization of $29.16 billion, a price-to-earnings ratio of 36.03, a price-to-earnings-growth ratio of 2.69 and a beta of 1.44. Illumina has a 52 week low of $88.00 and a 52 week high of $207.00. The firm has a 50-day moving average price of $184.48 and a 200 day moving average price of $150.83. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the business posted $1.19 earnings per share. The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Illumina will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In other news, insider Scott M. Davies sold 615 shares of the stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $200.00, for a total value of $123,000.00. Following the sale, the insider directly owned 20,338 shares in the company, valued at $4,067,600. This represents a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Scott D. Ericksen sold 1,500 shares of the firm's stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $150.10, for a total transaction of $225,150.00. Following the transaction, the chief accounting officer directly owned 14,946 shares of the company's stock, valued at approximately $2,243,394.60. This trade represents a 9.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,415,351 shares of company stock worth $255,966,311. 2.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ILMN. Fiduciary Financial Advisors acquired a new stake in Illumina during the 2nd quarter valued at $26,000. Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina in the second quarter worth $32,000. Rakuten Securities Inc. acquired a new position in shares of Illumina in the second quarter worth $33,000. Elyxium Wealth LLC purchased a new stake in shares of Illumina in the fourth quarter valued at $25,000. Finally, TD Waterhouse Canada Inc. acquired a new stake in shares of Illumina during the fourth quarter valued at $26,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source